Ecaterina E. Dumbrava

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-1959-0536

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 36 papers. Top paper: “Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials”.

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Journal of Clinical Oncology(2022)10.1200/jco.22.00830

N/A

2.2DataRank · unranked

97 citations

Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal +15 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0838

N/A

0.940DataRank · unranked

25 citations

Kurt W. Evans, Bailiang Wang, Ming Zhao, Argun Akçakanat, Maria Gabriela Raso +14 more

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Frontiers in Oncology(2022)10.3389/fonc.2022.818679

N/A

0.830DataRank · unranked

20 citations

Marcus O. Butler, Russell K. Pachynski, Ryan J. Sullivan, Partow Kebriaei, Sarah Boross-Harmer +20 more

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO Open(2021)10.1016/j.esmoop.2021.100230

N/A

0.564DataRank · unranked

42 citations

S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

npj Breast Cancer(2023)10.1038/s41523-023-00573-8

N/A

0.524DataRank · unranked

32 citations

Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans +8 more

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps2676

N/A

0.510DataRank · unranked

29 citations

Michael Dougan, Sarthak Gupta, Laura C. Cappelli, Tamiko R. Katsumoto, Osama E. Rahma +15 more

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

The Oncologist(2024)10.1093/oncolo/oyad338

N/A

0.510DataRank · unranked

29 citations

Binghe Xu, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam +20 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0.483DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

BMJ Oncology(2024)10.1136/bmjonc-2023-000133

N/A

0.473DataRank · unranked

13 citations

Genevieve Hartley, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas +18 more

Discordance of HER2 Expression and/or Amplification on Repeat Testing

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-22-0630

N/A

0.449DataRank · unranked

19 citations

Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant +5 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063

N/A

0.434DataRank · unranked

17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0762

N/A

0.385DataRank · unranked

12 citations

Thomas E. Stinchcombe, Mrinal M. Gounder, Gregory M. Coté, Glenn J. Hanna, Bradley Sumrall +16 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3952

N/A

0.330DataRank · unranked

8 citations

Filip Jankú, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp +20 more

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3158

N/A

0.292DataRank · unranked

6 citations

María E. Suarez‐Almazor, Jeane Painter, Tanner M. Johanns, Michael Dougan, Laura C. Cappelli +15 more

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009975

N/A

0.271DataRank · unranked

4 citations

Xinyan Xu, Girish S. Shroff, Nathan Comeaux, Wei Li, Jordi Rodon Ahnert +7 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0.269DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

Cancer(2023)10.1002/cncr.34773

N/A

0.269DataRank · unranked

5 citations

Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina A. Piha‐Paul, Julia Ann Moore +18 more

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

ESMO Open(2025)10.1016/j.esmoop.2025.104136

N/A

0.241DataRank · unranked

4 citations

Chieh Tseng, Hai T. Tran, Aung Naing, Ecaterina E. Dumbrava, DD Karp +9 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types

JCO Precision Oncology(2024)10.1200/po-24-00419

N/A

0.165DataRank · unranked

2 citations

Michael Kahle, Sun‐Hee Kim, Arash Ronaghy, Richard K. Yang, Keyur P. Patel +7 more

532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0532

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Serdar A. Gurses, Michelle York Gocio, Mohamed Omar Kaseb, Yali Yang +18 more

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005

N/A

0DataRank · unranked

72 citations

Cara Haymaker, Gabriela Raso, Serena Masciari, Lei Wang, Heather Lin +20 more

Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations

ESMO Open(2025)10.1016/j.esmoop.2025.105895

N/A

0DataRank · unranked

0 citations

Chieh Tseng, Hai T. Tran, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap +8 more

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0103

N/A

0DataRank · unranked

29 citations

Kurt W. Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q. Rizvi, Xiaofeng Zheng +11 more

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

JCO Precision Oncology(2022)10.1200/po.21.00456

N/A

0DataRank · unranked

30 citations

Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke +6 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Data from Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

(2023)10.1158/1078-0432.c.6528374.v1

N/A

0DataRank · unranked

0 citations

Amber M. Johnson, Ecaterina E. Dumbrava, Kanwal Raghav, Kavitha Balaji, Michelle Bhatt +4 more

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12117

N/A

0DataRank · unranked

0 citations

Sarina A. Piha‐Paul, Siqing Fu, Jordi Rodon Ahnert, Timothy A. Yap, Vivek Subbiah +10 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

OncoTargets and Therapy(2021)10.2147/ott.s291801

N/A

0DataRank · unranked

3 citations

Ecaterina E. Dumbrava, Binoj C. Nair, Wendy Xiong, Xu Li, Rosa Mostorino +12 more

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Cancer Biomarkers(2024)10.3233/cbm-230431

N/A

0DataRank · unranked

12 citations

Sunyoung S. Lee, Tarık Demir, Shadi Chamseddine, Zishuo Ian Hu, Lianchun Xiao +17 more

Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.47617

N/A

0DataRank · unranked

1 citations

Mirella Nardo, Cheuk Hong Leung, Heather Lin, Lei Kang, Hung Le +3 more